The pre-treatment lab panel for Mounjaro typically mirrors what is ordered for other GLP-1 medications, with a few considerations specific to tirzepatide:

• Comprehensive metabolic panel: Blood glucose, kidney function, liver enzymes, and electrolytes
• Hemoglobin A1c: Essential for patients with diabetes and highly informative for everyone else
• Lipid panel: Baseline cholesterol and triglycerides, which often improve with treatment
• TSH: Thyroid screening related to the boxed warning for thyroid C-cell tumors
• CBC: General health marker
• Amylase and lipase (if indicated): Pancreatic enzyme levels for patients with a history of or risk factors for pancreatitis

If you are already taking diabetes medications, your physician will pay close attention to glucose levels and A1c to adjust doses and prevent dangerous drops in blood sugar.

Mounjaro targets both the GIP and GLP-1 receptors, giving it a broader metabolic impact than single-receptor medications. This dual action means:

• Stronger glucose-lowering effect: Blood sugar can drop more rapidly and to a greater degree, requiring careful monitoring especially in diabetic patients
• More pronounced weight loss: Patients often lose 15% to 20% of their body weight, which creates significant shifts in metabolic markers
• Greater GI impact: The dual mechanism can produce more intense digestive side effects, increasing the risk of dehydration and kidney stress

All of these factors make regular lab monitoring not just recommended but practically necessary for safe, effective treatment.

For most patients, the following lab schedule provides adequate monitoring:

1. Pre-treatment: Complete baseline panel
2. 3 months: CMP and A1c recheck, with additional tests as clinically indicated
3. 6 months: Full panel including lipids to capture metabolic improvements
4. Every 6 to 12 months: Routine monitoring during maintenance

Patients with comorbidities (diabetes, kidney disease, liver disease) or those experiencing significant side effects may need more frequent testing. Your FormBlends physician will customize the schedule based on your individual needs. Mounjaro

If you are already taking Mounjaro without having had baseline labs, it is not too late to get them. Even mid-treatment labs provide valuable information. They can:

• Identify any developing kidney or liver concerns
• Establish a reference point for future monitoring
• Reveal whether your blood sugar and cholesterol are improving
• Detect thyroid abnormalities that should be evaluated

At FormBlends, if you transfer your care to us, we will order labs right away if none are on file. Getting tested mid-treatment is always better than not getting tested at all.

Absolutely. Mounjaro was originally developed and FDA-approved for type 2 diabetes, so glucose monitoring is especially critical for diabetic patients:

• A1c should be checked every 3 months until it stabilizes at goal levels
• Fasting glucose helps track day-to-day blood sugar management
• Medication adjustments may be needed: If you take insulin or sulfonylureas, your doses may need to be reduced to prevent hypoglycemia as Mounjaro lowers your blood sugar
• Kidney function is doubly important: Diabetes and dehydration from GI side effects both stress the kidneys

Our FormBlends physicians coordinate with your endocrinologist or primary care provider to ensure all diabetes medications are adjusted appropriately as your Mounjaro treatment progresses.

Mounjaro patients frequently see remarkable improvements in their lab work:

• A1c reductions: Average drops of 1.5 to 2.5 points in clinical trials, with some patients achieving normal A1c levels
• Lipid improvements: Triglycerides may drop by 20% to 30%, and LDL cholesterol often decreases
• Liver enzyme normalization: Patients with non-alcoholic fatty liver disease often see ALT and AST return to normal ranges
• Improved insulin sensitivity: Fasting insulin levels decrease as weight drops and metabolic function improves

These lab improvements represent real reductions in cardiovascular risk, diabetes progression, and overall mortality risk. They are among the strongest arguments for medically supervised weight loss.